The pooled RR for FAEs showed that the use of mTOR inhibitors significantly increased risk of developing FAEs in cancer patients with RR of 3.244 (95%CI: 1.214–8.667, p = 0.008, figure 3) using a fixed-effects model (I2  = 0%, p = 0.912). The gene discussed is MTOR; the disease is cancer.